Clinton Campaign Proposal Would Hamper Patient Access To Innovative New Cures and Therapies

Washington, D.C. (September 22, 2015) – Biotechnology Industry Organization (BIO) President and CEO Jim Greenwood issued the following statement today:

“The proposal released today by the Clinton campaign would do irreparable harm to the nation’s health innovation system, significantly hindering the ability of emerging biotechnology companies to develop the new cures and therapies that patients need to live longer, more productive lives. Intrusive government regulation of a system that relies on entrepreneurial vision and private capital is a recipe for failure. The provisions of the Clinton plan have been proposed many times in the past, and have always been rebuffed on a bipartisan basis because of the widely recognized fact that they are simply bad ideas for patients. We believe that fewer medicines would be produced and patient access to those medicines would be limited if the government set prices and became involved in private sector research and development.”

Upcoming BIO Events